

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

Multiple Sclerosis Journal
18(12) 1705–1717
© The Author(s) 2012
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1352458512438239
msj.sagepub.com


Deepak MW Balak¹, Gerald JD Hengstman^{2,3}, Aysun Çakmak⁴
and H Bing Thio¹

Abstract

Glatiramer acetate and interferon-beta are approved first-line disease-modifying treatments (DMTs) for multiple sclerosis (MS). DMTs can be associated with cutaneous adverse events, which may influence treatment adherence and patient quality of life. In this systematic review, we aimed to provide an overview of the clinical spectrum and the incidence of skin reactions associated with DMTs. A systematic literature search was performed up to May 2011 in Medline, Embase, and Cochrane databases without applying restrictions in study design, language, or publishing date. Eligible for inclusion were articles describing any skin reaction related to DMTs in MS patients. Selection of articles and data extraction were performed by two authors independently. One hundred and six articles were included, of which 41 (39%) were randomized controlled trials or cohort studies reporting incidences of mainly local injection-site reactions. A large number of patients had experienced some form of localized injection-site reaction: up to 90% for those using subcutaneous formulations and up to 33% for those using an intramuscular formulation. Sixty-five case-reports involving 106 MS patients described a wide spectrum of cutaneous adverse events, the most frequently reported being lipoatrophy, cutaneous necrosis and ulcers, and various immune-mediated inflammatory skin diseases. DMTs for MS are frequently associated with local injection-site reactions and a wide spectrum of generalized cutaneous adverse events, in particular, the subcutaneous formulations. Although some of the skin reactions may be severe and persistent, most of them are mild and do not require cessation of DMT.

Keywords

Interferon-beta, glatiramer acetate, skin reactions, adverse events, multiple sclerosis

Date received: 15th October 2011; revised: 14th January 2012; accepted: 16th January 2012

Introduction

Multiple sclerosis (MS) is a chronic, immune-mediated inflammatory disease of the central nervous system, which is characterized by infiltration of immune cells, loss of myelin and axons, and formation of multifocal plaques in the brain and the spinal cord.¹ MS is a common disease, with approximately 2.5 million people affected worldwide, most of whom are young and middle-aged adults.² At present, a definitive cure for MS is lacking so that its treatment is aimed primarily at reducing symptoms and disease progression via modulation of the immune system.³

To date, approved first-line disease-modifying therapies (DMTs) for the treatment of MS include glatiramer acetate (GA) and two types of interferon-beta (IFN- β): IFN- β -1a and IFN- β -1b. Both GA and IFN- β are assumed to affect

multiple immunological processes, but the exact mechanisms underlying their beneficial effects in MS are not fully understood.^{4,5} GA and IFN- β require administration via subcutaneous (SC) injections, while IFN- β -1a is also

¹Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands.

²Department of Neurology, Catharina Ziekenhuis, Eindhoven, The Netherlands.

³Regionaal MS Centrum Oost-Brabant, Eindhoven, The Netherlands.

⁴Department of Neurology, Amphia Ziekenhuis, The Netherlands.

Corresponding author:

HB Thio, Department of Dermatology, Erasmus Medical Center, Burg's Jacobsplein 51, 3015 CA Rotterdam, The Netherlands.
Email: h.thio@erasmusmc.nl

available as an intramuscular (IM) formulation. The dosage and frequency of administration differ between the four DMTs: GA is injected once daily, IFN- β -1b once every other day, SC IFN- β -1a three times a week, and IM IFN- β -1a once a week.

GA and IFN- β have proven albeit partial efficacy in reducing the frequency of relapses and disease activity, as shown by magnetic resonance imaging.^{6,7} Both therapies are generally safe and well-tolerated with an acceptable side-effect profile. However, patients treated with DMTs may frequently experience cutaneous adverse events.⁸ These cutaneous side-effects may include local injection-site reactions, such as erythema, induration, swelling, haemorrhage, pain, and pruritus around injection sites.^{9,10} Next to these usually transient injection-site reactions, more severe and persisting cutaneous complications to DMTs may occur, such as lipoatrophy and skin necrosis and ulcers.^{11,12} Cutaneous adverse events to DMTs can have important clinical implications as they may be associated with reduced treatment adherence and quality of life.

The aim of this systematic review is to provide an overview of the frequency and the spectrum of cutaneous adverse reactions associated with DMTs in MS patients.

Methods

Definitions

Adverse cutaneous events to DMTs were defined as any localized or generalized abnormality involving the skin during the treatment, regardless of the assumed causality with the drug. DMTs included SC glatiramer acetate (Copaxone[®], Sanofi Aventis and Teva), SC IFN- β -1a (Rebif[®], Merck Serono), IM IFN- β -1a (Avonex[®], Biogen Idec), and SC IFN- β -1b (Betaferon[®] and Betaseron[®], Bayer Schering).

Search strategy and selection criteria

An electronic literature search was performed up to 21 May 2011 in the MEDLINE, EMBASE, and Cochrane databases, including the Cochrane Multiple Sclerosis Group Trials Register, using combinations of the following keywords and/or medical subject headings (MeSH): 'glatiramer acetate', 'interferon-beta', 'multiple sclerosis', 'cutaneous reaction', 'skin', 'dermatology' and 'adverse event' (Supplement 1). We also included randomized controlled trials (RCTs) assessing the efficacy and safety of DMTs, considering that some of these trials may have had reported cutaneous adverse events as secondary or safety outcomes. Additional relevant articles were selected by screening the reference lists of included articles. Also, the manufacturers of GA and the IFN- β preparations were contacted for additional references.

Two authors (DMWB, AC) independently assessed the articles for eligibility for inclusion. Differences between the authors were resolved by a consensus agreement. Articles were first screened for relevance according to the title and the abstract. The remaining articles were then full-text assessed. Eligible for inclusion were articles describing any skin reaction or other dermatological symptom during treatment with one of the DMTs. Articles were excluded if they described diseases other than MS, if they did not describe adverse cutaneous events, or if they described medications other than GA or IFN- β . No limitations in language, study design, or study date were applied. Data were extracted from the included articles independently by two authors (DMWB, AC).

Results

Literature search

Our literature search yielded 1092 articles that were screened for eligibility, of which 106 articles were included (Supplement 2). There were two cross-sectional studies reporting the prevalence of cutaneous adverse events during DMT treatment. Thirty-nine (37%) of the included articles were RCTs or prospective follow-up studies that described general incidences of localized skin reactions to DMTs (Table 1). The other included articles (61%) were mostly case reports and case series that reported a total of 106 patients with a variety of localized and generalized cutaneous adverse events to DMTs (Table 2 and Table 3).

Local injection-site reactions

Incidences of local injection-site reactions were reported in most RCTs, but a majority of these trials used different definitions or did not specify their definition of local injection-site reactions. The used definitions of injection-site reaction in these trials included redness or erythema, swelling, pain, pruritus, bruising, irritation, inflammation, or induration of the skin around an injection site. In some of the RCTs, severity of the injection-site reactions was graded as mild, moderate, or severe. Also, some trials mentioned incidences of other cutaneous events, such as skin rash, cutaneous necrosis, and lipoatrophy. In only a few RCTs, adverse skin reactions were a primary outcome.^{52–55}

Table 1 gives an overview of the reported proportions of patients with injection-site reactions during DMT treatment. The RCTs are heterogeneous in their applied definition of skin reactions, sample size, follow-up duration and the used dosage or frequency of the DMT, among others, making it difficult to compare directly the incidences of injection-site reactions. Injection-site reactions developed in 2–33% of patients using IM IFN- β -1a. The proportion of patients with injection-site reactions for SC IFN- β -1a was between 13% and 89%, while about 22–96% of SC

Table 1. Summary of studies describing incidence or prevalence of cutaneous adverse events associated with glatiramer acetate and interferon-beta treatment for multiple sclerosis.

Study	Type of study	Number of patients	Follow-up duration	Treatment	Incidence of cutaneous adverse events	Cutaneous adverse events
Mikol et al (2008) ¹³	Randomized open-label study	378	1.8 years	GA 20 mg daily	7–30%	Injection-site reactions*
Meca-Lallana et al (2010) ¹⁴	Follow-up study	28	1–1.5 years	GA 20 mg daily	21%	Injection-site reactions
Wolinsky et al (2007) ¹⁵	RCT	627	3 years	GA 20 mg daily	9–57%	Injection-site reactions
Johnson et al (1995) ¹⁶	RCT	125	2 years	GA 20 mg daily	19–64%	Injection-site reactions
Korczyn et al (1996) ¹⁷	Database of multiple RCT data	857	—	GA (different dosages)	14–54%	Injection-site reactions
Zwibel (2006) ¹⁸	Open-label study	805	3.5 years	GA 20 mg daily	54%	Injection-site reactions
Comi et al (2011) ¹⁹	RCT	586	1 year	GA 20 mg daily	56%	Injection-site reactions
		569		GA 40 mg daily	58%	Injection-site reactions
Miller et al (2008) ²⁰	Open-label study	46	12 years	GA 20 mg daily	≥ 50%	Injection-site reactions
						Lipoatrophy (n=4)
O'Connor et al (2009) ²¹	Phase III RCT	445	2–3.5 years	GA 20 mg daily	58%	Injection-site reactions
Johnson et al (1998) ²²	Extension to RCT	125	2.5 years	GA 20 mg daily	66%	Injection-site reactions
Flechter et al (2002) ²³	Open-label study	38	2 years	GA 20 mg daily	70%	Injection-site reactions
				GA 20 mg eod	67%	Lipoatrophy (n=3 in daily group)
Flechter et al (2002) ²⁴	Open-label study	68	1–2 years	GA 20 mg eod	61%	Injection-site reactions
					7%	Rash
Debouverie et al (2007) ²⁵	Open-label study	205	4 years	GA 20 mg daily	81%	Injection-site reactions
Johnson et al (1995) ¹⁶	RCT	125	2 years	GA 20 mg daily	90%	Injection-site reactions
European Study group on IFN-β-1b in secondary progressive MS (1998) ²⁶	RCT	360	2–3 years	IFN-β-1b 250 ug eod	5%	Necrosis;
					21%	Rash
					44%	Injection-site reactions;
					50%	Inflammation
Gottesman et al (2006) ²⁷	Open-label study	22	0.4 years	IFN-β-1b 500 ug eod	22%	Injection-site reactions
Brochet et al (2006) ²⁸	RCT	294	0.1 years	IFN-β-1b (auto-injector)	24%	Rash/urticaria (n=1)
				IFN-β-1b	36%	Injection-site reactions
Durelli et al (2002) ²⁹	RCT	94	2 years	IFN-β-1b 250 ug eod	37%	Injection-site reactions
Neilley et al (1996) ³⁰	Open label study	72	—	IFN-β-1b 500 ug eod	42%	Skin reactions
Kappos et al (2006) ³¹	RCT	292	2 years	IFN-β-1b 250 ug eod	48%	Injection-site reactions
					11%	Rash
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) ³²	RCT	124	3 years	IFN-β-1b 500 ug eod	46–66%	Injection-site reactions
					4%	Injection-site necrosis

(Continued)

Table 1. (Continued)

Study	Type of study	Number of patients	Follow-up duration	Treatment	Incidence of cutaneous adverse events	Cutaneous adverse events
Hurwitz et al (2008) ³³	Randomised pilot study	33 38	0.2 years	IFN- β -1b 500 ug eod IFN- β -1b 250 ug eod	58% 66%	Injection-site reactions Injection-site reactions Rash (6–11%)
O'Connor et al (2009) ²¹	RCT	888 887	2–3.5 years	IFN- β -1b 250 ug eod IFN- β -1b 500 ug eod	48% 55%	Injection-site reactions Injection-site reactions
Kappos et al (2009) ³⁴	Extension to RCT	468	5 years	IFN- β -1b 250 ug eod	54%	Injection-site reactions
Baum et al (2006) ¹³	RCT	151 145	0.5 years	IFN- β -1b (with mannitol) IFN- β -1b (with glucose)	92% 96%	Injection-site reactions Injection-site reactions
Rio et al (1998) ³⁵	Prospective follow-up study	95	1 year	IFN- β -1b 500 ug eod	70%	Skin reactions
Montalban et al (2009) ³⁶	RCT	36	2 years	IFN- β -1b 250 ug eod	78%	Injection-site reactions
Flechter et al (2002) ²⁴	Open-label study	20	2 years	IFN- β -1b 250 ug eod	80%	Injection-site reactions
Reder et al (2010) ³⁷	Cross-sectional follow-up study of RCT	69	—	IFN- β -1b 250 ug eod	81%	Injection-site reactions
Cohen et al (2010) ⁷⁴	RCT	431	1 year	IM IFN- β -1a 30 ug/week	0.5%	Basal-cell carcinoma
Jacobs et al (1996) ³⁸	RCT	158	2 years	IM IFN- β -1a 30 ug/week	2%	Squamous-cell carcinoma
Havrdova et al (2009) ³⁹	Extension to RCT	60	3 years	IM IFN- β -1a 30 ug/week	3%	Injection-site reactions
Ghezzi et al (2007) ⁴⁰	Follow up study	52	1.8 years	IM IFN- β -1a 30 ug/week	4%	Erythematous rash
Schwid et al (2005) ⁴¹	Extension to RCT	223 272	0.6 years	IM IFN- β -1a 30 ug/week SC IFN- β -1a 44 ug TIW	33% 51%	Injection-site reactions Injection-site reactions
Sandberg-Wollheim et al (2005) ⁴²	RCT	338 339	1.2 years	IM IFN- β -1a 30 ug/week SC IFN- β -1a 44 ug TIW	30% 75%	Mild injection-site reactions (moderate 5%) Mild injection-site reactions (moderate 15%; severe 1%)
Herndon et al (2005) ⁴³	Extension to RCT	382	6 years	IM IFN- β -1a 30 ug/week	35%	Injection-site reactions
Durelli et al (2002) ²⁹	RCT	88	2 years	IM IFN- β -1a 30 ug/week	8%	Injection-site reactions
Leary et al (2003) ⁴⁴	RCT	15	2 years	IM IFN- β -1a 30 ug/week IM IFN- β -1a 60 ug/week	7% 15%	Injection-site reactions Injection-site reactions
Panitch et al (2002) ⁴⁵	RCT	337	0.5 years	IM IFN- β -1a 30 ug/week	28%	Injection-site reactions
Phillips et al (2004) ⁴⁶	Open-label study	153	2 years	IM IFN- β -1a 30 ug/week	31%	Injection-site reactions
Giovannoni et al (2009) ¹⁴	Open-label study	260	1.8 years	SC IFN- β -1a 44 ug TIW (Rebif new formulation)	31%	Injection-site reactions Rash (n=16)
Mikol et al (2008) ¹³	Randomized open-label study	381	1.8 years	SC IFN- β -1a 44 ug TIW	41%	Injection-site reactions Rash (n=28)
Freedman et al (2005) ⁴⁷	RCT	87 88	0.9 years	SC IFN- β -1a 22 ug TIW SC IFN- β -1a 44 ug TIW	13% 26%	Injection-site reactions Injection-site reactions

Table 1. (Continued)

Study	Type of study	Number of patients	Follow-up duration	Treatment	Incidence of cutaneous adverse events	Cutaneous adverse events
Andersen et al (2004) ⁴⁸	RCT	186	3 years	SC IFN- β -1a 22 ug/week	31%	Injection-site reactions
Oger et al (2005) ⁴⁹	RCT	87	2 years	SC IFN- β -1a 22 ug TIW	66%	Injection-site reactions
Panitch et al 2002 ⁴⁵	RCT	85	0.5 years	SC IFN- β -1a 44 ug TIW	66%	Abscess at injection site (n=1)
		339		SC IFN- β -1a 44 ug TIW	89%	Injection-site reactions Rash (n=56)
PRISMS study group (1998) ⁵⁰	RCT	189	2 years	SC IFN- β -1a 22 ug TIW	39%	Injection-site reactions
Devonshire et al (2010) ¹⁶	Prospective follow-up study	184	0.2 years	SC IFN- β -1a 44 ug TIW	40%	Injection-site reactions
		102		SC IFN- β -1a 44 ug TIW (Rebifect II)	76%	Injection-site reactions
Gold et al (2005) ⁵¹	RCT	189	4 years	SC IFN- β -1a 22 ug TIW	73%	Injection-site reactions (skin necrosis: n=7)
		184		SC IFN- β -1a 44 ug TIW	71%	Injection-site reactions (skin necrosis: n=13)
Lugaresi et al (2008) ¹⁵	Prospective follow-up study	76	1 year	SC IFN- β -1a 44 ug TIW (Rebifect)	79%	Injection-site reactions (n=50 persisted)
Panitch et al (2002) ⁴⁵	RCT	339	0.5 years	SC IFN- β -1a 44 ug TIW	83%	Injection-site reactions

*Injection site reactions include erythema, swelling, oedema, pain, pruritus, bruising, haemorrhage, irritation, and induration.

Abbreviations: eod, every other day; GA, glatiramer acetate; IFN- β , interferon beta; IM, intramuscular; NA, not applicable; RCT, randomized controlled trial; RRMS, relapsing remitting multiple sclerosis; SC, subcutaneous; TIW, three times a week.

Table 2. Case-reports and case-series describing cutaneous reactions to glatiramer acetate and interferon-beta treatment of multiple sclerosis.

Type of skin lesion	Total no. of case reports	Total no. of patients	Histology obtained (no. of patients)	DMT				Implications for treatment			
				GA	SC IFN-β-1a	IM IFN-β-1a	IFN-β-1b	Stopped	Continued	Unknown	
Lipoatrophy	8	30	20	28	1	-	1	29	1	-	-
Cutaneous ulcers	4	20	20	-	-	-	-	4	2	14	-
Cutaneous necrosis	12	15	9	2	1	-	20	6	4	5	-
Panniculitis	4	5	5	-	2	-	3	2	3	-	-
Urticaria	3	4	0	-	-	3	1	4	-	-	-
Cutaneous vasculitis	4	4	3	1	2	-	2	4	-	-	-
Embolia cutis medicamentosa	4	4	3	3	1	-	-	-	3	1	-
Lupus-like reactions	2	3	3	-	-	-	3	1	-	2	-
Psoriasis	3	3	1	-	1	-	2	1	1	1	-
Allergic local reactions	1	3	0	3	-	-	-	1	2	-	-
Systemic L.E.	1	1	0	-	1	-	-	-	-	-	-
Cutaneous LE	1	1	0	-	-	1	-	-	-	-	-
Fixed drug eruption	1	1	1	-	-	-	-	-	-	-	-
L.E. profundus	1	1	1	-	-	-	1	-	-	-	-
Scleromyxedema	1	1	1	-	-	1	-	-	-	-	-
Cutaneous mucinosis	1	1	1	-	-	-	1	-	-	-	-
Granulomatous dermatitis	1	1	1	-	-	-	-	-	-	-	-
Cutaneous T cell lymphoma	1	1	1	1	-	-	-	-	1	-	-
Cutaneous T cell pseudolymphoma	1	1	1	1	-	-	-	-	-	-	-
Calcifed noduli	1	1	1	-	1	-	-	-	-	-	-
Dermatomyositis	1	1	1	-	-	1	1	1	-	-	-
Subcutaneous infiltration	1	1	1	-	-	-	-	-	-	-	-
Erythema elevatum diutinum	1	1	1	-	1	-	-	-	-	-	-
Erythema nodosum	1	1	1	1	-	-	-	-	-	-	-
Nonscarring alopecia	1	1	0	1	-	-	-	-	-	-	-
Vitiligo	1	1	0	-	1	-	-	-	-	-	-

Abbreviations: DMT, disease-modifying therapy; GA, glatiramer acetate; IFN-β, interferon-beta; L.E., lupus erythematosus; SC, subcutaneous.

Table 3. The spectrum of cutaneous adverse reactions associated with the different disease-modifying treatments .

SC glatiramer acetate	SC IFN- β -1a	IM IFN- β -1a	SC IFN- β -1b
Lipoatrophy	Lipoatrophy	Cutaneous SLE	Lipoatrophy
Cutaneous necrosis	Cutaneous necrosis	Urticaria	Cutaneous ulcers
Panniculitis	Panniculitis	Drug eruption	Cutaneous necrosis
Cutaneous vasculitis	Cutaneous vasculitis	LEP	Panniculitis
Embolia cutis medicamentosa	Embolia cutis medicamentosa	Scleromyxedema	Cutaneous vasculitis
Cutaneous T cell lymphoma	Psoriasis		Cutaneous SLE/LEP
Cutaneous T cell pseudolymphoma	Calcified noduli		Lupus-like reactions
Erythema nodosum	Dermatomyositis		Psoriasis
Alopecia	Erythema elevatum diutinum		Granulomatous dermatitis
	Vitiligo		Subcutaneous infiltration
			Fixed drug eruption

Abbreviations: SC, subcutaneous; IFN, interferon; IM, intramuscular; SLE, systemic lupus erythematosus; LEP, Lupus erythematosus profundus.

IFN- β -1b patients and 7–90% of GA patients had developed local injection-site reactions.

Lipoatrophy

Lipoatrophy was a frequently reported adverse skin reaction, mostly in patients treated with GA. A prospective follow-up study reported that 4 (15%) out of 27 patients treated with GA had developed localized lipoatrophy at sites of injection after 3 years of treatment.¹² A larger, cross-sectional study from a single outpatient MS clinic in Canada found that 45% (34 out of 76) of patients with GA therapy had developed lipoatrophy after, on average, 2.4 years of treatment.⁵⁶ Another Canadian study assessed 100 consecutive patients receiving MS treatment, and reported 9 (64%) out of 14 patients treated with GA who had developed lipoatrophy.⁵⁷

There were multiple case reports and case series describing a total of 30 patients who developed lipoatrophy several years after initiation of GA (Table 2). In some of these cases, lipoatrophy persisted or continued to enlarge despite cessation of GA.^{58,59} There were two documented cases published in which lipoatrophy was associated with SC IFN- β -1a and IFN- β -1b, respectively.^{60,61} Some case reports reported a combination of panniculitis and lipoatrophy in association with GA or with IFN- β -1b.^{57,60,62}

Cutaneous ulcers and necrosis

Cutaneous ulcers were mainly described in patients who were treated with IFN- β -1b. A study by Webster and colleagues reported 8 (2%) out of 400 patients treated with IFN- β -1b who had developed skin ulcers.⁶³ Elgart and colleagues described 6 (6%) out of 100 consecutive patients on IFN- β -1b therapy with ulcers.⁶⁴

In addition, several published case reports reported an association between IFN- β -1b therapy and the development of cutaneous ulcers and skin necrosis at multiple injection sites.^{65–75} GA and SC IFN- β -1a have also been

linked to skin ulcerations with skin necrosis at injection sites in two case reports.^{75,76}

Embolia cutis medicamentosa, also known as Nicolau's syndrome, was described in four patients.^{77–80} Three of these patients were treated with GA, and one with SC IFN- β -1a. All patients experienced acute intense pain immediately after drug injection. The clinical features consisted of dark-red skin lesions with central necrosis and lightning-like extensions. The cause of Nicolau's syndrome is most probably related to the injection rather than the injected drug.⁷⁹ Consistent with this notion, all four patients could continue their treatment without complications of DMT treatment.

Immune-mediated cutaneous adverse events

There were multiple reports of various immune-mediated and inflammatory dermatological diseases in association with DMTs. Psoriasis, a common immune-mediated inflammatory skin disease, has been reported with IFN- β treatment in three patients.^{63,81,82} There were four case reports of cutaneous vasculitis as adverse cutaneous events to GA, SC IFN- β -1a, and IFN- β -1b (two patients).^{83–86} Erythema elevatum diutinum, a cutaneous type of vasculitis, was described in a patient treated with SC IFN- β -1a.⁸⁷ Panniculitis was described in three patients treated with IFN- β -1b and in two patients with SC IFN- β -1a.^{88–91} Nousari and colleagues described the development of cutaneous subacute lupus erythematosus in association with IM IFN- β -1a.⁹² Lupus-like reactions were described in four MS patients who were treated with IFN- β -1b.^{93–95} Cutaneous events with an inflammatory pathogenesis that were described only once in association with DMTs include dermatomyositis, erythema nodosum, scleromyxedema, lupus erythematosus profundus, vitiligo, and Jessner-Kanof benign lymphocytic infiltrate.^{96–101}

Allergic reactions

Allergic type 1 hypersensitivity reactions were reported mainly for GA. Three patients were reported who

developed pruritic wheals or erythema and itchy hives in response to GA injections.¹⁰² One of these patients was suspected of an IgE-mediated reaction to GA. There was a report of exacerbation of cholinergic urticaria during GA treatment.¹⁰³ Severe systemic allergic and anaphylactic reactions were reported in association with GA as well.^{104,105} Alava and colleagues described an atopic patient who developed allergic reactions to GA, and subsequently urticaria to IM IFN- β -1a.¹⁰⁶ Also, several reports were published on the development of widespread urticaria and angioedema to IM IFN- β -1a.^{107–109} Dimov and co-workers described a severe reaction with hives and angioedema of the extremities following IM IFN- β -1a injections.¹¹⁰ Brown and colleagues described an urticarial reaction in a patient treated with IFN- β -1b.¹¹¹

Cutaneous malignancies

One case report described the association between GA and a cutaneous lymphoma in a 33-year-old female MS patient who had developed a CD30-positive, primary, cutaneous, anaplastic large-cell lymphoma after four months of GA treatment.¹¹² After surgical excision and radiotherapy, remission was achieved and GA could be successfully continued in this patient. Skin cancers were reported several times in association with DMTs. In a RCT comparing the efficacy and safety of fingolimod to that of IM IFN- β -1a, there were reports of a squamous cell carcinoma and a basal cell carcinoma in two patients treated with IM IFN- β -1b compared to five basal cell carcinomas and three melanomas among those treated with fingolimod.¹¹³ Fruland and colleagues described a squamous cell carcinoma in a 47-year-old male MS patient who was treated with IFN- β -1b.¹¹⁴

Other cutaneous adverse events

Several skin reactions associated with DMTs were described only once or twice. Tai and Tam reported a fixed drug eruption associated with IFN- β -1b treatment, presenting as multiple erythematous plaques at non-injection sites.¹¹⁵ Another case report described a widespread macolopapular rash following IM IFN- β -1a injections with a positive prick test to IFN- β -1a.¹¹⁶ Other less frequently occurring cutaneous adverse events reported among MS patients receiving DMTs were granulomatous dermatitis, subcutaneous infiltrate, calcified subcutaneous nodule and alopecia.^{117–120}

Discussion

We performed a systematic review of the literature to describe the incidence and the clinical spectrum of cutaneous adverse events in patients treated with DMTs for MS. Incidences of cutaneous adverse events were reported in several RCTs and a few prospective follow-up studies.

Available data from these studies showed that a substantial proportion of MS patients receiving DMTs developed local injection-site reactions during their treatment. Up to approximately 90% of patients treated with GA and SC IFN- β had developed local skin reactions. The incidence among patients treated with IM IFN- β -1a appeared to be lower, with up to 33% of these patients developing skin reactions. There were no major differences in the occurrence of injection-site reactions between the different dosages of the DMTs. Next to the local injection-site skin reactions, there were many case reports and case series of more severe, generalized and sometimes persisting cutaneous adverse events described in association with DMTs. Frequently reported cutaneous adverse events to DMTs in MS patients were lipoatrophy, skin necrosis and ulcers. In addition, a wide variety of dermatological diseases associated with DMTs were described, including various immune-mediated inflammatory skin diseases, such as psoriasis, vasculitis, and lupus-like reactions. Most of these dermatological reactions were rare and described only once. In several cases, cessation of DMT or switching to another DMT was required.

Several limitations need to be considered. Firstly, a systematic review of adverse events is challenging with regard to the literature search. We cannot exclude the possibility that relevant articles were missed in our literature search. Secondly, definitions of skin reactions were not uniform among the included RCTs, making it difficult to compare these or to calculate a risk estimate for the incidence of skin reactions. Thirdly, RCTs in general measure only common, short-term adverse events. There were only a few observational (cross-sectional and cohort) studies available that assessed cutaneous adverse events in MS patients treated with DMTs. Case reports do provide information on the occurrence of less frequent side-effects, but a definitive causal relationship with the DMT is not always clear. Furthermore, there were only few studies that assessed cutaneous adverse events as a primary outcome.

Several mechanisms have been postulated by which DMTs induce skin reactions. Most theories focus on immune-mediated mechanisms, including local inflammatory reactions, IgE-mediated reactions, delayed hypersensitivity reactions and other immune reactions.¹²¹ Buttman and colleagues showed that SC IFN- β is able to induce local chemokine production, which can lead to inflammatory skin reactions.¹²² Consistent with this, several of the reported cutaneous adverse events have an immune-mediated pathogenesis, such as psoriasis and vasculitis. Mechanical injury due to injections seems less likely to play an important role in the development of these cutaneous adverse events. Embolia cutis medicamentosa, however, seems to be the only exception as it is associated with the injection itself rather than with the drug injected.^{79,121}

Based upon the results of our literature review lipoatrophy seemed more frequently reported in association with GA in comparison to the other DMTs. A majority of the

cases with lipoatrophy were linked to GA. However, there were reports of lipoatrophy in two patients treated with SC IFN- β -1a and IFN- β -1b, respectively. By contrast, cutaneous necrosis was reported solely in relationship to SC IFN- β -1b. For the other types of cutaneous adverse events, there was no clear relationship with a specific DMT. Still, the evidence for the occurrence of specific adverse events associated with a specific DMT is limited given that prospective studies designed to assess the incidences of cutaneous adverse events with each DMT are lacking.

Several immune-mediated cutaneous adverse events were described in association with DMT, including associations with psoriasis, lupus erythematosus and dermatomyositis. A definite causal role of the DMT was not clearly established in most of these case-reports, making it unclear whether the associations with immune-mediated cutaneous adverse events are truly attributable to the DMT. Somani and colleagues have provided experimental evidence supporting a causal role of interferon treatment in the development of dermatomyositis as a cutaneous adverse event to DMT.⁹⁶ Still, the reported immune-mediated cutaneous events may be related to MS itself rather than to the DMT, considering the described associations between MS and other immune-mediated diseases such as inflammatory bowel disease and bullous pemphigoid.^{123,124} Alternatively, treatment with DMT may pose an additional increased risk to develop immune-mediated cutaneous adverse events in patients with multiple sclerosis.

Cutaneous malignancies associated with DMT were reported in a few RCTs and case reports, but DMT-use does not seem to be associated with an increased risk of skin cancer. A French cohort study did not find an increased risk of skin cancer among MS patients treated with DMT.¹²⁵ Similarly, a recent analysis of data from several RCTs and data from a global drug safety database showed that long-term treatment with SC IFN- β -1a was not associated with malignancies, including melanoma skin cancer. However, non-melanoma skin cancers were not included in these analyses.¹²⁶

It is interesting to compare the incidence of cutaneous adverse events associated with DMTs to that of injectable therapies for other chronic diseases, even though direct comparisons are lacking. Studies in patients with inflammatory bowel disease who were treated with subcutaneous anti-tumour necrosis factor alpha inhibitors demonstrated a relatively high incidence of skin reactions and a broad spectrum of cutaneous adverse events.¹²⁷ Similar high incidences were reported for rheumatoid arthritis patients treated with daily subcutaneous injections of a interleukin-1 receptor antagonist.¹²⁸

The occurrence of skin reactions may lead to cessation of the DMT or switching to another type DMT. Given that dermatologists have experience in the diagnosis and treatment of immune-mediated inflammatory skin diseases, they may help in assessing and treating the skin reactions induced by DMTs without the necessity of stopping or switching the DMT.

Future research should aim at assessing the determinants of cutaneous adverse events in long-term treatment with DMT in large observational studies, such as cumulative injections, anatomical site correlations and dose dependency. Furthermore, it would be of interest to assess if there is a correlation between the occurrence of skin reactions and the efficacy of the DMT. Another interesting research question for future studies is whether cutaneous reactions to DMT are associated with a decrease in treatment adherence. In a large multicentre observational study among 2648 patients, injection-related problems were a commonly cited reason for non-adherence.⁵⁵ Furthermore, it would be relevant to assess the impact of skin reactions on patient quality of life. If there is a significant clinical impact, it would be helpful to assess interventions to prevent or reduce the onset of cutaneous adverse events. Attempts have been made already to prevent local skin reactions via oral antihistamines and warm compresses.^{129,130}

In conclusion, this systematic review shows that DMTs in MS are frequently associated with local injection-site reactions and a wide range of other cutaneous adverse events.

Funding

This review was funded by an educational grant of Biogen Idec.

Conflict of interests

DMW Balak declared no conflict of interest.

GJD Hengstman has received consulting fees and lecture fees from Biogen Idec, Merck-Serono, Novartis and Sanofi-Aventis.

A Çakmak declared no conflict of interest.

HB Thio has received research, speaking and consulting support from Biogen Idec.

References

1. Frohman EM, Racke MK and Raine CS. Multiple sclerosis – the plaque and its pathogenesis. *N Engl J Med* 2006; 354: 942–955.
2. Compston A and Coles A. Multiple sclerosis. *Lancet* 2008; 372: 1502–1517.
3. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. *Nat Rev Drug Discov* 2010; 9: 883–897.
4. Dhib-Jalbut S and Marks S. Interferon-beta mechanisms of action in multiple sclerosis. *Neurology* 2010; 74 Suppl 1: S17–S24.
5. Racke MK, Lovett-Racke AE and Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. *Neurology* 2010; 74 Suppl 1: S25–S30.
6. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing–remitting multiple sclerosis. *Cochrane Database Syst Rev* 2001: CD002002.
7. La Mantia L, Munari LM and Lovati R. Glatiramer acetate for multiple sclerosis. *Cochrane Database Syst Rev* 2010: CD004678.

8. Walther EU and Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. *Neurology* 1999; 53: 1622–1627.
9. Frohman EM, Brannon K, Alexander S, et al. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. *Mult Scler* 2004; 10: 302–307.
10. Langer-Gould A, Moses HH and Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. *Neurology* 2004; 63: S35–S41.
11. Ball NJ, Cowan BJ and Hashimoto SA. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases. *J Cutan Pathol* 2009; 36: 331–337.
12. Mancardi GL, Murialdo A, Drago F, et al. Localized lipatrophy after prolonged treatment with copolymer 1. *J Neurol* 2000; 247: 220–221.
13. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. *Lancet Neurol* 2008; 7: 903–914.
14. Meca-Lallana JE, de Mingo-Casado P, Amarin-Diaz M, et al. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing–remitting multiple sclerosis: a prospective, non-randomized, open-label, uncontrolled, observational pilot study. *Clin Ther* 2010; 32: 1061–1066.
15. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. *Ann Neurol* 2007; 61: 14–24.
16. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology* 1995; 45: 1268–1276.
17. Korczyn AD and Nisipeanu P. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. *J Neurol* 1996; 243: S23–26.
18. Zwibel HL. Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. *Acta Neurol Scand* 2006; 113: 378–386.
19. Comi G, Cohen JA, Arnold DL, et al. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. *Ann Neurol* 2011; 69: 75–82.
20. Miller A, Spada V, Beerkircher D, et al. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing–remitting multiple sclerosis. *Mult Scler* 2008; 14: 494–499.
21. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurol* 2009; 8: 889–897.
22. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. *Neurology* 1998; 50: 701–708.
23. Flechter S, Kott E, Steiner-Birmanns B, et al. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration. *Clin Neuropharmacol* 2002; 25: 11–15.
24. Flechter S, Vardi J, Pollak L, et al. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. *J Neurol Sci* 2002; 197: 51–55.
25. Debouverie M, Moreau T, Lebrun C, et al. A longitudinal observational study of a cohort of patients with relapsing–remitting multiple sclerosis treated with glatiramer acetate. *Eur J Neurol* 2007; 14: 1266–1274.
26. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. *Lancet* 1998; 352: 1491–1497.
27. Gottesman MH and Friedman-Urevich S. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS). *Mult Scler* 2006; 12: 271–280.
28. Brochet B, Lemaire G and Beddiaf A. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. *Revue Neurologique* 2006; 162: 735–740.
29. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). *Lancet* 2002; 359: 1453–1460.
30. Neille LK, Goodin DS, Goodkin DE, et al. Side effect profile of interferon beta-1b in MS: results of an open label trial. *Neurology* 1996; 46: 552–554.
31. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology* 2006; 67: 1242–1249.
32. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. *Neurology* 1996; 47: 889–894.
33. Hurwitz BJ, Jeffery D, Arnason B, et al. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing–remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. *Clin Ther* 2008; 30: 1102–1112.
34. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurol* 2009; 8: 987–997.
35. Rio J, Marzo ME, Tintore M, et al. [Profile of efficacy and safety in the treatment of remittent-recurrent multiple sclerosis with interferon beta-1b] Perfil de eficacia y seguridad en el tratamiento de la esclerosis multiple remitente-recurrente con interferon beta-1b. *Neurologia* 1998; 13: 422–426.

36. Montalban X, Sastre-Garriga J, Tintore M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. *Mult Scler* 2009; 15: 1195–1205.
37. Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-(beta)-1b for relapsing–remitting MS. *Neurology* 2010; 74: 1877–1885.
38. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Ann Neurol* 1996; 39: 285–294.
39. Havrdova E, Zivadinov R, Krasensky J, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. *Mult Scler* 2009; 15: 965–976.
40. Ghezzi A, Amato MP, Capobianco M, et al. Treatment of early-onset multiple sclerosis with intramuscular interferon-beta-1a: long-term results. *Neurol Sci* 2007; 28: 127–132.
41. Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. *Arch Neurol* 2005; 62: 785–792.
42. Sandberg-Wollheim M, Bever C, Carter J, et al. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. *J Neurol* 2005; 252: 8–13.
43. Herndon RM, Rudick RA, Munschauer FE, 3rd, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. *Mult Scler* 2005; 11: 409–19.
44. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. *Neurology* 2003; 60: 44–51.
45. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. *Neurology* 2002; 59: 1496–1506.
46. Phillips JT, Rice G, Frohman E, et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. *Clin Ther* 2004; 26: 511–521.
47. Freedman MS, Francis GS, Sanders EA, et al. Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. *Mult Scler* 2005; 11: 41–45.
48. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2004; 75: 706–710.
49. Oger J, Francis G and Chang P. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study. *J Neurol Sci* 2005; 237: 45–52.
50. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. *Lancet* 1998; 352: 1498–1504.
51. Gold R, Rieckmann P, Chang P et al. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing–remitting multiple sclerosis: 4-year data from the PRISMS study. *Eur J Neurol* 2005; 12: 649–656.
52. Baum K. Safety and tolerability of a ‘refrigeration-free’ formulation of interferon beta-1b—results of a double-blind, multicentre, comparative study in patients with relapsing–remitting or secondary progressive multiple sclerosis. *J Int Med Res* 2006; 34: 1–12.
53. Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. *Mult Scler* 2009; 15: 219–228.
54. Lugaresi A, Durastanti V, Gasperini C, et al. Safety and tolerability in relapsing–remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. *Clin Neuropharmacol*. 2008; 31: 167–172.
55. Devonshire V, Arbizu T, Borre B, et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. *BMC Neurology* 2010; 10.
56. Edgar CM, Brunet DG, Fenton P, et al. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. *Can J Neurol Sci* 2004; 31: 58–63.
57. Ball NJ, Cowan BJ, Moore GR et al. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing–remitting multiple sclerosis. A report of two cases. *J Cutan Pathol* 2008; 35: 407–410.
58. Soos N, Shakery K and Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. *Am J Clin Dermatol* 2004; 5: 357–359.
59. Hashimoto S, Ball N and Tremlett H. Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report. *Mult Scler* 2009; 15: 521–522.
60. Beiske AG and Myhr KM. Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis. *J Neurol* 2006; 253: 377–378.
61. O’Sullivan SS, Cronin EM, Sweeney BJ, et al. Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2006; 77: 1382–.
62. Soares Almeida LM, Requena L, Kutzner H, et al. Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study. *J Am Acad Dermatol* 2006; 55: 968–974.
63. Webster GF, Knobler RL, Lublin FD, et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. *J Am Acad Dermatol* 1996; 34: 365–367.
64. Elgart GW, Sheremata W and Ahn YS. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. *J Am Acad Dermatol* 1997; 37: 553–558.
65. Ozden MG, Erel A, Erdem O, et al. Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta 1a injection in a multiple sclerosis patient. *J Eur Acad Dermatol Venerol* 2005; 19: 112–113.

66. Casoni F, Merelli E, Bedin R, et al. Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b. *Mult Scler* 2003; 9: 420–423.
67. Yang CH, Chen CH and Chan HL. Skin necrosis following a recombinant interferon-beta-1b injection. *Chang Gung Med J* 2002; 25: 774–777.
68. Garcia FVM, Dauden E, Sanchez J, et al. Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b. *Acta Derm Venereol* 2001; 81: 152.
69. Albani C and Albani G. A case of cutaneous necrosis during interferon-beta 1b (B-IFN) therapy in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 1997; 62: 418.
70. Creange A and Lefaucheur JP. Focal neuropathy associated with cutaneous necrosis at the site of interferon-beta injection for multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2000; 68: 395.
71. Sheremata WA, Taylor JR and Elgart GW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. *N Engl J Med* 1995; 332: 1584.
72. Ohata U, Hara H, Yoshitake M, et al. Cutaneous reactions following subcutaneous beta-interferon-1b injection. *J Dermatol* 2010; 37: 179–181.
73. Feldmann R, Low-Weiser H, Duschet P, et al. Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis. *Dermatology* 1997; 195: 52–53.
74. Weinberg JM, Wolfe JT, Sood S, et al. Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature. *Acta Derm Venereol* 1997; 77: 146–148.
75. Radziwill AJ and Courvoisier S. Severe necrotising cutaneous lesions complicating treatment with interferon beta-1a. *J Neurol Neurosurg Psychiatry* 1999; 67: 115.
76. Bosca I, Bosca M, Belenguer A, et al. Necrotising cutaneous lesions as a side effect of glatiramer acetate. *J Neurol* 2006; 253: 1370–1371.
77. Koontz D and Alsheklee A. Embolia cutis medicamentosa following interferon beta injection. *Mult Scler* 2007; 13: 1203–1204.
78. Feldmann R, Schierl M, Rauschka H, et al. Necrotizing skin lesions with involvement of muscle tissue after subcutaneous injection of glatiramer acetate. *Eur J Dermatol* 2009; 19: 385.
79. Harde V and Schwarz T. Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate. *J Dtsch Dermatol Ges* 2007; 5: 1122–1123.
80. Gaudez C, Regnier S, Aractingi S, et al. [Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1 (Glatiramer acetate)] Dermite livedoide de Nicolau apres injection de Copolymere-1 (acetate de Glatiramer). *Rev Neurol (Paris)* 2003; 159: 571–573.
81. Lopez-Lerma I, Iranzo P and Herrero C. New-onset psoriasis in a patient treated with interferon beta-1a. *Br J Dermatol* 2009; 160: 716–717.
82. Navne JE, Hedegaard U and Bygum A. [Activation of psoriasis in patients undergoing treatment with interferon-beta] Aktivering af psoriasis hos patienter i interferon-beta-behandling. *Ugeskr Laeger* 2005; 167: 2903–2904.
83. Szilasiova J, Gdovinova Z, Jautova J, et al. Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis. *Clin Neuropharmacol* 2009; 32: 301–303.
84. Cohen BA, Greenberger PA and Saini S. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b. *Allergy Asthma Proc* 1998; 19: 85–88.
85. Debat Zoguereh D, Boucraut J, Beau-Salinas F, et al. [Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis]. *Rev Neurol (Paris)* 2004; 160: 1081–1084.
86. Cicek D, Kandi B, Oguz S, et al. An urticarial vasculitis case induced by glatiramer acetate. *J Dermatolog Treat* 2008; 19: 305–307.
87. Gil M, Chizzolini C, Kaya G et al. Erythema elevatum et diutinum, multiple sclerosis and interferon beta. *Dermatology* 2004; 209: 75–76.
88. Heinzerling L, Dummer R, Burg G, et al. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient. *Eur J Dermatol* 2002; 12: 194–197.
89. Poulin F, Rico P, Cote J, et al. Interferon beta-induced panniculitis mimicking acute appendicitis. *Arch Dermatol* 2009; 145: 916–917.
90. Nakamura Y, Kawachi Y, Furuta J, et al. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection. *Eur J Dermatol* 2008; 18: 579–582.
91. Soria A, Maubec E, Henry-Feugeas MC, et al. [Panniculitis induced by interferon beta-1a vascular toxicity]. *Ann Dermatol Venereol* 2007; 134: 374–377.
92. Nousari HC, Kimyai-Asadi A and Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. *Lancet* 1998; 352: 1825–1826.
93. Conroy M, Sewell L, Miller OF, et al. Interferon-beta injection site reaction: review of the histology and report of a lupus-like pattern. *J Am Acad Dermatol* 2008; 59: S48–49.
94. Arrue I, Saiz A, Ortiz-Romero PL and Rodriguez-Peralto JL. Lupus-like reaction to interferon at the injection site: report of five cases. *J Cutan Pathol* 2007; 34 Suppl 1: 18–21.
95. Benito-Leon J, Borbujo J and Cortes L. Cutaneous mucinosis complicating interferon beta-1b therapy. *Eur Neurol* 2002; 47: 123–124.
96. Somani AK, Swick AR, Cooper KD, et al. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. *Arch Dermatol* 2008; 144: 1341–1349.
97. Thouvenot E, Hillaire-Buys D, Bos-Thompson MA, et al. Erythema nodosum and glatiramer acetate treatment in relapsing–remitting multiple sclerosis. *Mult Scler* 2007; 13: 941–944.
98. Kumar N and Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. *Mult Scler* 2004; 10: 85–86.
99. Gono T, Matsuda M, Shimojima Y, et al. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient. *J Clin Neurosci* 2007; 14: 997–1000.
100. Kocer B, Nazliel B, Oztas M, et al. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report. *Eur J Neurol* 2009; 16: e78–79.
101. Nolden S, Casper C, Kuhn A, et al. Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate. *Mult Scler* 2005; 11: 245–248.

102. Sanchez-Lopez J, del Rio PR, Cases-Ortega B, et al. Allergy workup in immediate-type local reactions to glatiramer acetate. *J Investig Allergol Clin Immunol* 2010; 20: 521–523.
103. Batista J, Ponce V, Hierro B, et al. Transient exacerbation of cholinergic urticaria during concomitant treatment with glatiramer acetate. *Allergy* 2010; 65: 246.
104. Bayerl C, Bohland P and Jung EG. Systemic reaction to glatiramer acetate. *Contact Dermatitis* 2000; 43: 62–63.
105. Rauschka H, Farina C, Sator P, et al. Severe anaphylactic reaction to glatiramer acetate with specific IgE. *Neurology* 2005; 64: 1481–1482.
106. Alava C, Tornero P, Prieto A, et al. Anaphylaxis with glatiramer acetate and delayed urticarial reaction to interferon beta-1a in a multiple sclerosis patient with chronic urticaria. *Allergy* 2010; 65: 242.
107. Mazzeo L, Ricciardi L, Fazio MC, et al. Severe urticaria due to recombinant interferon beta-1a. *Br J Dermatol* 2003; 148: 172.
108. Fusun Kalpaklioglu A, Baccioglu Kavut A and Erdemoglu AK. Desensitization in interferon-beta 1a allergy: a case report. *Int Arch Allergy Immunol* 2009; 149: 178–180.
109. Guijarro C, Benito-Leon J and Bermejo-Pareja F. Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis. *Neurol Sci* 2011; 32: 309–311.
110. Dimov V, Sandhu M and Bewtra A. Repeat desensitizations in interferon beta-1a and beta-1b allergy: a case report. *Ann Allergy, Asthma Immunol* 2009; 103: A83.
111. Brown DL, Login IS, Borish L, et al. An urticarial IgE-mediated reaction to interferon beta-1b. *Neurology* 2001; 56: 1416–1417.
112. Madray M, Butler DF and Greene J. Glatiramer acetate-associated CD30+ primary cutaneous anaplastic large-cell lymphoma. *J Am Acad Dermatol* 2009; 60: AB128.
113. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med* 2010; 362: 402–415.
114. Fruland JE, Sandermann S, Snow SN, et al. Skin necrosis with subsequent formation of squamous cell carcinoma after subcutaneous interferon beta injection. *J Am Acad Dermatol* 1997; 37: 488–489.
115. Tai YJ and Tam M. Fixed drug eruption with interferon-beta-1b. *Australas J Dermatol* 2005; 46: 154–157.
116. Serarslan G, Okuyucu E, Melek I, et al. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis. *Mult Scler* 2008; 14: 259–261.
117. Mehta CL, Tyler RJ and Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. *J Am Acad Dermatol* 1998; 39: 1024–1028.
118. Ziegler VR, Kranke B, Soyer P, et al. [Extensive cutaneous–subcutaneous infiltration as a side-effect of interferon-beta injection]. *Hautarzt* 1998; 49: 310–312.
119. Macbeth AE, Kendall BR, Smith A, et al. Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy. *Br J Dermatol* 2007; 157: 624–625.
120. Pacheco MF, Jacobe H, Eagar TN, et al. Reversible alopecia associated with glatiramer acetate. *Arch Neurol* 2010; 67: 1154.
121. Kluger N, Thouvenot E, Camu W, et al. Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone). *J Eur Acad Dermatol Venereol* 2009; 23: 1332–1333.
122. Buttman M, Goebeler M, Toksoy A, et al. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. *J Neuroimmunol* 2005; 168: 175–182.
123. Nielsen NM, Frisch M, Rostgaard K, et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. *Mult Scler* 2008; 14: 823–829.
124. Langer-Gould A, Albers KB, Van Den Eeden SK, et al. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. *Mult Scler* 2010; 16: 855–861.
125. Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. *Mult Scler* 2008; 14: 399–405.
126. Sandberg-Wollheim M, Kornmann G, Bischof D, et al. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings. *Mult Scler* 2011; 17: 431–440.
127. Baumgart DC, Grittner U, Steingraber A, et al. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. *Inflamm Bowel Dis* 2011; 17: 2512–2520.
128. Kaiser C, Knight A, Nordstrom D, et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. *Rheumatol Int* 2011.
129. Jolly H, Simpson K, Bishop B, et al. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. *J Neurosci Nurs* 2008; 40: 232–239.
130. Pardo G, Boutwell C, Conner J, et al. Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate. *J Neurosci Nurs* 2010; 42: 40–46.